Member Info for TorquayFan

Thanks Billy. Looks like a helpful step forward for Merck - hopefully Keytruda intradermal is ok too for the Combo with iSCIB1+ for the melanoma trial ? Anyway, what with iSCIB1+ and Pharmajet, all good news.

Simply to note that this 34% improvement in PFS, (77% over 43%), can be looked at differently, maybe by a Patient , (if not by Pharma). 77% is actually 79% higher than 43% . Getting on for the doubling a Patient's chances of this level of response ! I'd be very interested in that as a Patient. E. & O.E.

Pepe - "I can't help feeling the departure of a CFO is significant".

Chilltime 26790 over there, suggests : "I understand he will be part of a very exciting entity. The idea came about 3 years ago set to get going this year, backed by someone very prominent and very very wealthy. You’ll soon see why".

I commented earlier, "I suspect Redmile had indicated the need for a major player as CFO and that the 'heads up' had been given." So Sath may in fact have had some time to find himself another role, (comforted by his ample share options).

Good luck to Sath who did an admirable job at Scancell, But we've moved on. I think the arrival of David Schilansky to cover the the CFO role 'in transition', probably leaves Scancell in a better place.

So IMHO no negative scenario to be found on this point. ATB

It also occurs to me that if Scancell is in fact headed for the Nasdaq, it may be possible that, post Schilansky. a new permanent CFO might be based in the USA ?

Just a shot in the dark . . .

Van - we don't know at all that Sath left 'so quickly', or Chester, that he left 'at such pace'. Yesterday 10.01, I commented, "I suspect Redmile had indicated the need for a major player as CFO and that the 'heads up' had been given." So Sath may in fact have had some time to find himself another role, (comforted by his ample share options).

Whilst nothing can be ruled out, I think it unlikely that a Company acquiring Glymab would not have the organisation/personnel to absorb the acquisition without needing our erstwhile CFO.

Moonparty - if Genmab are making a move for Glymab then occasional 'access to Lindy and the technical team' might be needed but remember that Genmab have had their own wizards working with glycans for some years now so they already know plenty.

All good fun - one thing is for sure. News is due !

I'm not the first to ponder so, but I'm guessing Team Phil are nearing a deal for one part of Scancell, the most likely candidate to be Glycans, lock, stock and barrel. The funds raised will be used to take Scancell forward to a US listing, the corporate strategy being pushed by Redmile, who want to take the science in Project Lindy all the way!

Best wishes to Sath who has now moved on - I suspect Redmile had indicated the need for a major player as CFO and that the 'heads up' had been given. Good luck to Sath who did a great job and will get stellar rewards through his share options in due course, one hopes.

David Schilansky is already in place and will bring skills to help make the deal AND help set Scancell on a new way forward.

More important is a point for Torquay Utd lunchtime, to secure a place in the playoffs ! Nice weekend all.

Commiserations Ray. Maybe 60 years ago (?) when Burnley were table toppers, I saw them beat West Ham at Upton Park, 4-5!

As I support Swindon Town, Fulham, Torquay United and Nakhon Ratchasima, (just relegated from TPL), I am quite familiar with the pain. I remember Pointer, Angus, Elder, McIlroy, Connelly, Lochhead etc.

I was surprised to see the yellow banner above, asking for support for 'Phil' in this weekend's London Marathon. I checked it out and am pleased to say, it's apparently not our Phil.

But plenty of time for Mr L'Huillier to start training for the 2027 event !

An intrigueing series of posts over there from Chilltime, 26735 - 26743, on the background and possible implications of the Eric Rubin presence on Scancell's Advisory Board. Hard to know how this might affect what and how and from where a deal might come, but it's good to have him around !

Thanks Chilltime - an early start and hard work !

The AACR starts tomorrow, Friday, so maybe an RNS is coming in the next few days, or today ?

Apart from possible news re. Glycans it seems to me a Modi1 update is due ?

Also inside this link on Marcus 26647 : "BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot. BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S. BioNTech is closing a Singapore production plant less than four years after buying the site from Novartis to supply mRNA vaccines and therapies in the Asia-Pacific region.

When BioNTech bought the facility in November 2022, the company expected the facility to be fully operational in late 2023 and create more than 100 jobs. This week, BioNTech told The Straits Times that the planned Singapore site will close by the end of February. The company employs 85 people at the plant. BioNTech framed the shuttering of the facility as part of efforts to align capacity with its pipeline and long-term strategic direction. The company bought the plant to support clinical and commercial supply of its mRNA vaccines and therapeutics across the Asia-Pacific region. However, BioNTech’s R&D pipeline subsequently diversified beyond mRNA, setting the company up for growth even as Health Secretary Robert F. Kennedy Jr. came down hard on the technology over the past year. In August, Kennedy canceled around $500 million in BARDA contracts associated with mRNA vaccine development, for example. “Under the FDA and [Health Secretary] RFK Jr., it really feels like they’ve declared war on mRNA vaccines,” Piper Sandler analyst Ted Tenthoff said at an event with Moderna in December 2025""

https://www.biospace.com/business/biontech-starts-shuttering-singapore-mrna-manufacturing-site-amid-pipeline-pivot

Marcus then comments : "So it’s obvious they would have a significant interest in the whole sector via CPIs with Scancell’s DNA vaccine. That news adds to the likelihood of them having a keen interest. Arguably you could say Biontech are in a dangerous situation where they need to break free of reliance on mRna vaccines, and sharpish. They are well aware of Scancell having officially linked up pre Covid (as in an RNS at the time). Covid vaccines then completely dominated what Biontech were doing.

Biontech were chasing the Melanoma sector. Just like others they combined a checkpoint inhibitor (Libtayo) with their mRna vaccine, in pretreated stage 3/4 cases. They achieved fasttrack post stage 2 but the phase 3 didn’t hit the mark, reported August 2025. Phase 2 figures were PFS 24.9% at 24 months. That is a subset of Melanoma the pre treated poor responders."

So BioNTech could be in the frame for M&A activity in direction Scancell, as "mRNA technology continues to face headwinds in the U.S." Food for thought . . . .

I think Sath is to be congratulated for adeptly helping Scancell through these last few years. Impressive also that he managed to give product presentations with credibility. Wishing Sath every success in the future and hoping that he gets a fat reward for those share options in due course.

Redmile understandably wanted a known package of David's considerable experience and skills in place and in charge, for this phase of Scancell's development. I suppose for Sath, it was a 'job done' situation, with a meaty payoff in prospect via the options.

Again Scancell increasingly looks to be, ready for serious action !

Whoops - Johnny I'd missed your point which would certainly explain the conundrum. Back to sleep!

Chester - maybe Sath has retained those 2 million share options ?

""Scancell Holdings plc. Scancell announces CFO transition

David Schilansky to be appointed as financial advisor and interim CFO, bringing extensive industry and financial experience, including leading IPOs on Nasdaq and Euronext. Ensures continuity as Scancell advances iSCIB1+ Phase 3 trial and builds shareholder value.

Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces David Schilansky, a highly experienced senior healthcare executive and entrepreneur, and Entrepreneur-in-Residence with Redmile Group, has been appointed (with immediate effect) to serve as a financial advisor and shall become interim Chief Financial Officer (CFO) later in April. Current CFO Sath Nirmalananthan has indicated he will be leaving the Company and will step down from the Board of Directors as of April 24, 2026 to pursue other professional opportunities. Scancell has launched a global recruitment process for a permanent CFO.

Dr Phil L'Huillier, CEO of Scancell, said: "David brings broad and strategic financing expertise to Scancell and will be a strong interim CFO, ensuring continuity and progress in our strategy. We remain laser focused on delivering iSCIB1+ to patients and building shareholder value. Having David in place enables us to seamlessly advance our constructive financing and partnering discussions on our lead ImmunoBody® iSCIB1+, now with the recently obtained strong regulatory feedback in hand. Further, David brings valuable investor engagement and strategic financing expertise, including Nasdaq listing experience that will help guide the company as we explore a potential listing in the US."

Phil L'Huillier added: "Sath has played an important role at Scancell, providing strong financial guidance and preparing us for our next phase of development. On behalf of the Scancell team, I would like to thank Sath for his dedicated and committed efforts to Scancell. We wish him all the best in his future endeavours."

David Schilansky is a seasoned pharma and biotech executive and is currently concluding his role as Chief Executive Officer of Ariceum Therapeutics and commencing as Venture Partner and Entrepreneur-in-Residence at Redmile Group. He was previously CEO and co-founder of Home Biosciences from 2020 to 2025, which created three biotech companies (One Biosciences, Sequantrix and Apikal Therapeutics). From 2011 to 2019, he co-headed DBV Technologies, leading its IPOs on Nasdaq and Euronext, raising a total of more than $1 billion. Prior to that, he held several leadership roles in finance, including Group CFO at Ipsen.""

Thanks Saf but welcome to David !

HTTps://youtu.be/bCBick9kvNE

hTTps://www.prnewswire.com/news-releases/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xten-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer-302694866.html

Over there Chilltime 26535 and Inanaco replies follow . . .

https://vjumer.info/118c5/0-peptide-vaccines-for-cancer/

Scancell features again . . .

Hi all. For me it's news any day ! We're well down the path to the next RNS.

We'll see. Have a good weekend . . .

Yes Violin I think that title remains squarely yours and you have no real competitors. However your posts don't help or achieve anything. It's clear you are not in a position to get out and you are not alone.

I have 100% faith in where this is going and have decided to try and put up with the wait.

Yes thanks Bermuda. In view of this, "it's possible that accelerated dosing may lead to some improvement" I think as Scancell have decided to use the accelerated dosing after cohort 4, at least we can be assured they will know enough, that PFS responses from Phase 3, will be maintained, on these grounds at least. Some improvement is possible as you say . . . . hopefully.